About us - Nanjing Yier Biotechnology Co., Ltd.

Engaging in the R&D, production or sales of various innovative medical devices

Nanjing Yier Biotechnology Co., Ltd. was founded in 2016. It is a subsidiary under Hospital & Homecare Group, established to serve as a vehicle for entering new medical business areas, engaging in the R&D, production or sales of various innovative medical devices, and sharing resources such as Hospital & Homecare Group's brand and sales channels so on.

Corporate Culture

Global Leader

Leveraging experience in 130 countries and dual CE/ISO13485 certifications, we have built a global medical device service system.

Innovation Breakthrough

We focus on innovative R&D in products such as silicone urinary catheters, continuously overcoming bottlenecks in biocompatibility and clinical application technology.

Quality First

Using non-toxic, odorless, and non-corrosive silicone materials as our core, we ensure our products are safe, low-irritant, and meet stringent international standards.

Professional Support

Led by a team of experienced medical engineers, we provide comprehensive professional services, from operational training to after-sales support.

Synergy and Win-Win

We are committed to working in sync with our customers, employees, and partners, sharing long-term, mutually beneficial development outcomes.

Comprehensive Care

From preoperative compression hemostasis to postoperative drainage and cleaning, we provide full-lifecycle warranty training and technical response support.

Development History

In 2016, Establishment and Launch: As a subsidiary of a hospital and home care group, focusing on the R&D and production of silicone urinary catheters, it began its strategic layout in the field of innovative medical devices.

In 2017-2018, Certification Breakthrough: Successfully obtained CE/ISO 13485 dual certification and a free sale certificate, laying the foundation for global compliance qualifications.

In 2019-2021, Market Expansion: Silicone urinary catheters (including all sizes from F6 to F26 and special balloon models) were sold to dozens of countries worldwide, forming a sales network covering more than 130 countries.

In 2022, Service Upgrade: Building a "full-process medical care" service system, integrating preoperative training, intraoperative support, and postoperative maintenance, strengthening global customer collaborative response capabilities.

In 2025, Strategic Deepening: Relying on market experience in 130 countries and a professional team, advancing the "global leadership" vision, and building a one-stop comprehensive medical service system covering all diagnosis and treatment scenarios.

Built upon three core strengths—an integrated service network, a strong expert team, and a global market presence we create a differentiated competitive advantage in the medical device field.

Comprehensive Healthcare Support

Providing one-stop services including preoperative adaptation, intraoperative training, and postoperative maintenance to ensure safe and efficient application across all scenarios.

Professional Elite Leadership

Led by a professional team, covering material analysis, operating procedures, and certification interpretation, our technology precisely meets clinical needs.

Global Collaboration

Leveraging a market network spanning 130 countries, we achieve rapid response and multilingual support, building a global system for sharing high-quality products.

Honors and Certifications

Our biotechnology company places great emphasis on quality management and technical standards, and therefore we have obtained numerous certifications and certificates to demonstrate our professional capabilities and product quality.